Ardelyx Outlines Next Phase III Steps For Tenapanor, Ditches RDX7675
Executive Summary
New Phase III study of tenapanor in hyperphosphatemia will include an active control arm for safety monitoring, per US FDA guidance, slightly lengthening timeline.